Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2014 - 2026)

Jazz Pharmaceuticals has reported Long-Term Investments for 12 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 45.07% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 45.07% YoY), and the FY2025 full-year result was $1.0 billion, up 81.03% from the prior year.
• Long-Term Investments for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Long-Term Investments was $1.0 billion in Q4 2025, with the low at $60.0 million in Q2 2022.
• Average Long-Term Investments over 5 years is $467.1 million, with a median of $440.0 million recorded in 2024.
• Year-over-year, Long-Term Investments surged 681.25% in 2024 and declined 23.2% in 2025.
• Tracing JAZZ's Long-Term Investments over 5 years: stood at $60.0 million in 2022, then jumped by 100.0% to $120.0 million in 2023, then soared by 383.33% to $580.0 million in 2024, then jumped by 81.03% to $1.0 billion in 2025, then retreated by 1.9% to $1.0 billion in 2026.
• The last three Long-Term Investments figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $720.0 million (Q3 2025), per Business Quant data.

Peer Comparison